Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Recruiting

Phase 2

Camizestrant & AtirmociclibStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Sponsor:

AstraZeneca

Code:

NCT07427394

Conditions

Advanced Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Camizestrant

Atirmociclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-24. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-06-16.